In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?

被引:12
|
作者
Swords, Ronan [1 ]
Santini, Valeria [2 ]
机构
[1] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Div Hematol Oncol, Miami, FL 33136 USA
[2] Univ Florence, AOU Careggi, Florence, Italy
关键词
ACUTE MYELOID-LEUKEMIA; TRANSPLANTATION COMORBIDITY INDEX; INTENSIVE CHEMOTHERAPY; OLDER PATIENTS; EARLY DEATH; AGE; SURVIVAL; RISK; DECISION; OUTCOMES;
D O I
10.1182/asheducation-2012.1.74
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
A 75-year-old man visits his primary care physician for a routine checkup and a complete blood count reveals pancytopenia. BM examination confirms the diagnosis of acute myeloid leukemia. No dysplastic features were noted and his karyotype results are pending. The patient has well-controlled hypertension and his last hospital admission was 20 years ago for repair of a rotator cuff injury. His Eastern Cooperative Oncology Group performance status is 0/4 and he has no cognitive impairment. You believe the patient is fit for standard acute myeloid leukemia induction, but you are concerned because of his older age and you are considering less-intensive approaches.
引用
收藏
页码:74 / 75
页数:2
相关论文
共 50 条
  • [1] Which patients should be considered for gene therapy
    Miesbach, Wolfgang
    JOURNAL OF VIRAL HEPATITIS, 2024, 31 : 9 - 13
  • [2] What Is the Optimal Induction Therapy for Younger Fit Patients With AML?
    Hugo F. Fernandez
    Current Hematologic Malignancy Reports, 2016, 11 : 327 - 332
  • [3] What Is the Optimal Induction Therapy for Younger Fit Patients With AML?
    Fernandez, Hugo F.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (05) : 327 - 332
  • [4] AML: How to characterize and treat elderly patients non fit for standard treatment
    Spiekermann, K.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S10 - S10
  • [5] Clofarabine in previously untreated elderly (>65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy.
    Burnett, A. K.
    Baccarani, M.
    Johnson, P.
    Yin, J.
    Russell, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 340S - 340S
  • [6] Amsacrine containing induction therapy in elderly AML patients:: Comparison to standard induction regimens in a matched-pair analysis
    Kessler, T.
    Mohr, M.
    Mueller-Tidow, C.
    Krug, U.
    Brunnberg, U.
    Mohr, B.
    Schliemann, C.
    Sauerland, C.
    Serve, H.
    Buechner, T.
    Berdel, W. E.
    Mesters, R. M.
    LEUKEMIA RESEARCH, 2008, 32 (03) : 491 - 494
  • [7] Amsacrine containing induction therapy in elderly AML patients: Comparison to standard induction regimens in a matched pair analysis.
    Mohr, M
    Mohr, B
    Brunnberg, U
    Albrecht, O
    Sargin, B
    Grote, A
    Sauerland, MC
    Heinecke, A
    Zuhlsdorf, M
    Buchner, T
    Berdel, WE
    Serve, H
    BLOOD, 2003, 102 (11) : 239B - 239B
  • [8] Is there a standard induction regimen for patients with AML?
    Ravandi, Farhad
    Cortes, Jorge
    Kantarjian, Hagop
    LANCET ONCOLOGY, 2013, 14 (07): : 565 - 566
  • [9] Efficacy and tolerability of FLAG as induction therapy in elderly AML patients.
    Leoni, F
    Ciolli, S
    Santini, V
    Nozzoli, C
    Ferrini, PR
    BLOOD, 1999, 94 (10) : 233B - 233B
  • [10] Family therapy should be considered for patients with schizophrenia
    Arroll, Megan
    JOURNAL OF PRIMARY HEALTH CARE, 2014, 6 (04) : 339 - 339